Quality, Affordable and Accessible

Archive for the ‘Uncategorized’ Category.

HuaiYin Hospital Serves Another Record Number of Patients in 2017

January 19, 2018

Sinophi-invested HuaiYin Hospital in Huai’an City, Jiangsu province (next to Shanghai) provided treatment for a total of 547,923 out-patients in 2017 (up from 537,195 in 2016), an average of more than 1,500 patients served each day.  In-patient numbers also increased to 48,799 (up from 47,740 in 2016).  These service figures surpass the previous record breaking levels achieved in 2016.

Sinophi Healthcare invested in HuaiYin Hospital in 2014.  It is a Class AA, formerly public, hospital with over 1,000 beds located in the central HuaiYin District of Huai’an City.  As the second largest hospital in Huai’an City, the hospital serves the approximately one million residents of HuaiYin District and attracts patients from across the other urban and rural areas of Huai’an City and its 5.5 million inhabitants.

Sinophi Healthcare meets with China’s President Xi Jinping and UK Prime Minister David Cameron

London, October 21, 2015

During the State Visit to the UK, Sinophi Healthcare Chairman Simon MacKinnon and Chief Operating Officer Gong Yongqiang met with China’s President Xi and Prime Minister Cameron.

President Xi Jinping meeting with Sinophi Chairman Simon MacKinnon and Sinophi COO Gong Yongqiang

Commenting, Gong Yongqiang, COO of Sinophi Healthcare Ltd, said: “It was a great honour for Sinophi to meet the national leaders and to have their support for our £800 million of hospital investments in China focused on oncology and treating cancer.  The Sinophi Proton Centre projects with top AAA hospitals in Beijing, Changchun, Fuzhou, Huai’an, Luoyang and Nanjing will make proton therapy more affordable and widely available to cancer patients. With our Chinese hospital partners we are bringing together the best of Chinese oncology and radiotherapy expertise with the next generation of proton therapy equipment from the UK to benefit all patients”

State Leaders President Xi Jinping and Prime Minister David Cameron 

Seven China hospital deals worth £800 million focused on proton therapy to treat cancer

London, October 21, 2015

Sinophi Healthcare, the China hospital investment and management company, announces today that during the State Visit to the UK by China’s President Xi Jinping, the company has signed seven hospital deals in China worth £800 million.  These are focused on proton therapy to treat cancer.   The seven hospitals include one oncology hospital with a proton centre and one maternity hospital in the city of Huai’an, as well as five Sinophi Proton Centres in Beijing, Changchun, Fuzhou, Luoyang and Nanjing with a combined total investment in building, infrastructure, operation and costs of £800 million.  

Following meeting with China’s President Xi Jinping and UK Prime Minister David Cameron, a signing ceremony was held in London witnessed by the UK Minister of State for Life Sciences Mr George Freeman MP.   Sinophi Healthcare’s Dr Hanif Kanji, Chief Executive, and Professor Zhao GuoQing, President of the China-Japan Union Hospital of Jilin University signed a deal to build a Sinophi Proton Centre at the hospital.  It was also announced that a purchase order was signed with Advanced Oncotherapy plc for a LIGHT proton therapy machine for the facility.  The China-Japan Union Hospital is located in Changchun, Jilin Province and is one of the largest hospitals in NE China with 3,328 beds.

Professor Zhao GuoQing, President of the China-Japan Union Hospital of Jilin University, signing the agreement with Sinophi CEO Dr Hanif Kanji with  UK Minister of State for Life Sciences Mr George Freeman MP looking on

At the signing ceremony Sinophi announced Framework Agreements to build four other Sinophi Proton Centres. These have been signed with Beijing Shijitan Hospital affiliated with Capital Medical University in Beijing; Nanjing Drum Tower Hospital affiliated with Nanjing University Medical School in Nanjing, Jiangsu Province; Luoyang Central Hospital affiliated to Zhengzhou University, in Luoyang, Henan Province and Fuzhou City Health Bureau in Fuzhou, Fujian Province.

These Sinophi Proton Centres in China bring together the best of Chinese oncology treatment and expertise with the advanced proton therapy technology of Advanced Oncotherapy plc of the UK.

China currently has one proton centre in Shanghai.  The combined population of the six Chinese cities where the Sinophi Proton Centres will be located is over 60 million people, with patients also expected to come from neighbouring cities and provinces (Jiangsu, Henan, Hebei, Fujian and Jilin provinces) with another 250 million people.

The two announced Sinophi Healthcare hospital deals in the city of Huai’an are for an oncology hospital with a proton centre, and for a maternity hospital.  These will be built in partnership with the Huai’an First People’s Hospital (3,000 beds) and with Huai Yin Hospital (1,000 beds).  Sinophi China Hospital Holdings Limited, a company invested by Sinophi Healthcare, Morgan Stanley Private Equity Asia, Sihuan Pharmaceutical and Euromax has already invested in Huai Yin Hospital.

Commenting on the signings, Dr Hanif Kanji, CEO of Sinophi Healthcare Ltd said: “The UK and China have many shared challenges dealing with cancer. Our Sinophi Proton Centres in six of China’s leading cities will expand to more Chinese cities in future.  We support the objectives of the Chinese Government’s healthcare reform programme by making proton treatment widely available at reduced cost, saving lives and improving the quality of life of cancer patients.  The next generation proton therapy technology of Advanced Oncotherapy plc, developed at their ADAM subsidiary (a spin-off from CERN in Geneva), will enable many more people to benefit in their treatment from the greater accuracy and fewer side effects of proton therapy compared to X-ray radiotherapy.”

Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said: “I am delighted to have signed our second commercial purchase order for our LIGHT system. This, and the further Framework Agreements being signed today, are a testament to the successful partnership between Sinophi’s strong healthcare network in China and our ground-breaking proton therapy technology. The advantages of our technology over existing products is generating strong interest across China. With over 20% of the world’s newly diagnosed cancer cases coming from China this market represents a huge opportunity for us.”

About Sinophi Healthcare

Sinophi Healthcare is a UK company which invests in and manages hospitals in China, focused on public general hospitals and selected specialty and super specialty hospitals. Sinophi works in partnership with hospitals in China’s rapidly growing urban areas to deliver improvements in the delivery of healthcare. Sinophi brings to hospitals in China international hospital expertise and technology, building links with hospitals in the UK’s National Health Service system and partnerships with leading UK and international healthcare service and product partners.

Sinophi Healthcare signs an MOU with Vernacare of the UK, meets with BIS Secretary of State Mr Sajid Javid MP

September 23^rd 2015

Sinophi Healthcare and Bolton-based Vernacare signed an MOU to deliver £10 million in business to Vernacare over the next 5 years in Sinophi’s hospitals in China.

Sinophi is looking to reduce infections in its hospitals by using Vernacare’s hygienic single-use system for patient toileting and washing.  Vernacare’s system and products are used in 96% of the UK’s NHS Trusts, reducing risks of cross-infection, freeing up nursing time, reducing damage to the environment and producing cost savings.

Lord O’Neill of Gatley, Commercial Secretary to the Treasury, witnessed the signing in Shanghai together with Seif Usher, Assistant Director, UKTI China Life Sciences, Health and Social Care.  At the signing Lord O’Neill noted Sinophi’s work with leading UK suppliers of healthcare products and services and the many opportunities for Vernacare and other UK healthcare companies to grow their exports and their businesses in China. He also highlighted the growing UK-China cooperation in addressing the major global challenge of reducing AMR (antimicrobial resistance).

The signing took place during the visit to China by Chancellor Osborne of the UK with a large delegation of Ministers, business and cultural leaders.

Sinophi Chairman Simon MacKinnon signs with Emma Sheldon, Vernacare Marketing Director,

with Lord O’Neill of Gatley and Seif Usher.

Following the signing, Sinophi provided the Secretary of State for Business Innovation and Skills, Mr Sajid Javid MP, with an update on Sinophi’s hospital investment plans in China.  These include building Proton Centres using next generation proton therapy treatment machines from the UK’s Advanced Oncotherapy plc to give many more patients in China access to the benefits of proton therapy for cancer treatment.

Secretary of State for Business Innovation and Skills, Mr Sajid Javid MP, with Simon MacKinnon

Sinophi Signs Agreement for Proton Centre with China-Japan Union Hospital of Jilin University

On July 27th 2015 in Changchun, Jilin province, China, Sinophi Healthcare signed an agreement with China-Japan Union Hospital of Jilin University (CJUHJU) for a Proton Center at CJUHJU in Changchun. The Proton Center will include a proton therapy machine from Advanced Oncotherapy plc of the UK, using world-leading advanced proton technology developed at CERN in Switzerland. Changchun Vice Mayor Madame Zhang Jing Ying, Jilin University President Mr Li Yuan Yuan and China Development Bank Jilin Province Deputy General Manager Mr Zhang Zhao Yi attended the signing ceremony together with Mr Brian Gallagher, Director, UKTI China representing the UK Government. The agreement was signed by Professor Zhao Guo Qing, President of CJUHJU and Dr Hanif Kanji, CEO of Sinophi Healthcare.

Commenting on the agreement, Mr Li Yuan Yuan, President of Jilin University, said: “I believe Sinophi Healthcare and the China-Japan Union Hospital of Jilin University will be a powerful combination, with the construction of a proton therapy center a mutually beneficial opportunity which will also create other opportunities and platforms. Jilin University is delighted to support this advanced scientific and technological project to bring to Changchun, Jilin and China the latest proton treatment to relieve the pain of cancer patients.

Commenting on the agreement, Professor Zhao Guo Qing, President of China-Japan Union Hospital of Jilin University, said: “Our hospital’s cooperation with Sinophi Healthcare to build a proton therapy center will enable us to lead in developing the next generation of proton therapy in China. It will give our physicians new tools to treat cancer patients and to contribute to improving the healthcare of the citizens we serve in Changchun City, in Jilin Province and throughout northeast China.”

Commenting on the agreement, Dr Hanif Kanji, CEO of Sinophi Healthcare said: “The Sinophi Proton Center in Changchun continues Sinophi’s commitment to work with leading Chinese hospitals to support the objectives of China’s healthcare reform programme. Our cooperation with China-Japan Union Hospital of Jilin University is our first investment in next generation, high precision medicine in China. Our goal is to reduce the equipment, operation and maintenance costs of proton radiotherapy so many more cancer patients can have access to the benefits of proton therapy in China. This Sinophi Proton Center is a wonderful example of making the benefits of a major breakthrough in medical technology available to all people.

About China-Japan Union Hospital of Jilin University

CJUHJI is located in Changchun in Jilin province and is one of north-east China’s leading hospitals. Founded in 1949 and formerly known as the Number 3 Affiliated Hospital of the Norman Bethune Medical University, today it is a AAA grade hospital with 3,328 in-patient beds. Under the direct jurisdiction of the National Health and Family Planning Commission and affiliated to Jilin University under the Education Ministry of China, CJUHJI integrates medical care, education, research, disease-prevention, healthcare and rehabilitation into one institution.

About Jilin University
Located in Changchun City, Jilin University is one of China’s leading universities and one of the largest, with over 60,000 students. Jilin University has established ties with 130 universities, colleges and research institutes in 40 countries. In addition to the China-Japan Union Hospital, the Changchun No 1 and No 2 Hospitals are also part of Jilin University.

About Changchun City
Changchun City has a population of more than 7.8 million and is the provincial capital of Jilin province (population 27 million). Known as China’s leading manufacturing location for automobiles and transportation equipment and as a major film production center, Changchun is a leading city in the north-east China region.

About proton therapy
There are three main forms of treatment for cancer: surgery, chemotherapy and radiotherapy. X-ray radiotherapy is the most used form of radiotherapy today. Proton therapy, using the energy released by protons to destroy cancer cells, is another form of radiotherapy. It is a validated treatment for cancer used since 1954, with more than 120,000 patients treated globally since then. Proton therapy is better able than X rays to target tumours and not surrounding organs, leading to reduced side effects and better quality of life for patients. It can reduce length of treatment and thus cost, and is particularly beneficial when tumours are located close to vital organs and for children with cancer.

About Advanced Oncotherapy plc  (www.avoplc.com)

Advanced Oncotherapy is a UK company listed on AIM on the London Stock Exchange (stock symbol: AVO).  Advanced Oncotherapy’s  subsidiary “ADAM”, a spin-off company from CERN based in Geneva, has developed the next-generation proton therapy systems for cancer treatment.  Advanced Oncotherapy and its LIGHT machine system greatly reduces the cost of proton beam therapy for cancer treatment and brings it within reach of many more patients.

About CERN  (www.cern.ch)
CERN is the European Centre for Nuclear Reasearch, located near Geneva in Switzerland.  CERN is one of the world’s largest and most respected centers for scientific research and the inventor of the most powerful particle accelerator ever built, the 27km Hadron Collider.

About Sinophi Healthcare  (www.sinophi.com)
Sinophi Healthcare is a UK company investing in and managing hospitals in China, focused on public general hospitals and selected specialty and super specialty hospitals. Sinophi works in partnership with hospitals in China’s rapidly growing urban areas to deliver improvements in the delivery of healthcare. Sinophi brings to hospitals in China international hospital expertise and technology, building links with hospitals in the UK’s National Health Service system and partnerships with leading UK and international healthcare service and product partners.

Sinophi completes US$130 million project with Huai Yin Hospital in Huai’An City, Jiangsu Province, China

December 29, 2014

Sinophi China Hospitals Holdings Limited announced today a US$130 million project with Huai Yin Hospital in Huai’An City, Jiangsu Province.  Sinophi China Hospitals Holdings Limited is a company invested by Sinophi Healthcare, Morgan Stanley Private Equity Asia (MSPEA), Sihuan Pharmaceutical (Sihuan) and Euromax.  MSPEA, Sihuan and Euromax hold their investment in Sinophi China Hospitals Holdings Limited through a joint venture, Renfang Medical Holdings Ltd.

Simon MacKinnon, Chairman of Sinophi China Hospitals Holdings Limited and Sinophi Healthcare noted “Huai Yin Hospital is the first hospital invested by Sinophi China Hospitals Holdings in mainland China. We are committed to actively participating in the Chinese Government’s reforms of the healthcare system by investing in public hospitals, building new hospitals and bringing together international healthcare resources with leading Chinese hospitals, doctors and nurses in Huai’An and other cities.  Our hospitals will support the Chinese Government’s goals of delivering more accessible, more cost-effective and better quality healthcare services to all Chinese citizens.”

NOTES:

Huai’An City

Huai’An City (population 5.5 million) is located in Jiangsu province (population 80 million, next to Shanghai) in East China.  Huai’An City is a famous cultural and trading center on the Grand Canal and is the hometown of former Chinese Premier Zhou Enlai.

Huai Yin Government and Huai Yin Hospital

Huai Yin District (population around one million) is in the center of Huai’An City.  The Huai Yin District Government administers the Huai Yin Hospital, the largest district-level hospital in Huai Yin District in Huai’An City in Jiangsu Province. It is the third largest hospital in Huai’An City in terms of bed count.

The Huai Yin Hospital has been recognised as one of the best local level II general hospitals in HuaiAn City.  It covers a total of 116,000 square meters and gross floor area of 56,000 square meters with 1,085 beds, 17 functional departments and 24 clinical medical departments.  The departments of general surgery and urinary surgery are the two municipal key clinical specialties. The hospital has achieved over a 100% bed utilization rate for the past three years with over 490,000 annual outpatient visits in 2013.

Rapid economic development has contributed to a surge in local medical demand, which underpins Huai Yin Hospital’s important market position in Huai’An City.

Sinophi Healthcare

Sinophi Healthcare is a UK company focused on investing in and managing hospitals in China. Target businesses include public and private general hospitals as well as specialty hospitals.  Sinophi’s hospitals deliver quality, value-for-money healthcare in China’s rapidly growing urban areas. Sinophi brings international hospital expertise, links with hospitals in the UK’s National Health Service system and with leading UK and international healthcare partners to its hospitals in China.

Morgan Stanley Private Equity Asia

MSPEA is one of the leading private equity investors in Asia Pacific, having invested in the region for over 20 years. MSPEA invests primarily in highly structured minority investments and control buyouts in growth-oriented companies at attractive valuations. The experienced investment team is led by senior professionals with extensive industry relationships, in-depth market knowledge and the ability to apply international investment principles within each local context. MSPEA has offices in Hong Kong, Beijing, Shanghai, Seoul, Tokyo, Mumbai and New York, and leverages the brand and unparalleled global network of Morgan Stanley to source investment intelligence and opportunities. MSPEA is part of Morgan Stanley Merchant Banking & Real Estate Investing.

Sihuan Pharmaceutical Holdings Group Limited

Sihuan Pharmaceutical is a Hong Kong listed company (stock code: 0640).  Sihuan is a leading pharmaceutical Company with the largest cardio-cerebral vascular drug franchise in China’s prescription drug market by market share. The Group has a differentiated and proven sales and marketing model, supported by an extensive nationwide distribution network covering around 10,000 hospitals through over 3,000 distributors in all 31 provinces, autonomous regions and cities throughout the PRC.

Euromax is wholly-owned by Dr. Che Fengsheng, an executive Director of Sihuan and a substantial shareholder in Sihuan. The principal activity of Euromax is investment holding.

China healthcare sector

According to McKinsey data, the Chinese healthcare sector is set to grow at over 12% per annum, with total healthcare spend to exceed US$1 trillion by 2020.

According to the Chinese Centre for Disease Control and Prevention, Beijing, the major causes of disease and death in China have shifted from predominantly infectious disease and diet-related deficiency diseases to non-communicable diseases (NCDs) including hypertension, stroke, coronary heart disease, diabetes, cancers, etc. These account for 85% of deaths today (up from 50% four decades earlier).  China’s considerable efforts in healthcare reform are addressing the increased demand on the system from NCDs. The NCD burden in China continues to grow with recent studies estimating 114 million diabetics in China with another 493 million in a pre-diabetic state.

Following the twelfth Five Year Plan and the latest waves of healthcare reform commencing in 2009, Chinese government policy is encouraging the involvement of private and foreign capital into healthcare services and is targeting 20% of inpatient visits and beds to be serviced by the private sector by 2020 from current levels of below 10%.

For further information please contact:

Simon MacKinnon                  simon.mackinnon@sinophi.com

Prime Minister Cameron and Secretary of State for Health Hunt support Sinophi in China

December 3rd, 2013

In Shanghai today, UK Prime Minister David Cameron MP met with Sinophi Healthcare Chairman Simon MacKinnon and senior government officials from Huai’an City in Jiangsu Province in East China in support of deals worth UK£120 million between Sinophi and Huai’an City, Jiangsu Province signed in Beijing.

The signing ceremony took place in Beijing on December 2nd, with UK Minister of State for Trade and Industry Lord Livingston, Mr Tang Daolun, Vice Mayor of Huai’an Municipal People’s Government and Dr Catherine Raines, Minister and Director-General of UKTI China witnessing the signings.  These were for a joint venture to do hospital management with Huai’an First People’s Hospital (HAFPH), and two LOIs for a hospital acquisition and to build a 1,000 bed regional oncology centre in Huai’an City.

Speaking about Sinophi’s work in Huai’an, Prime Minister Cameron said “This deal highlights the enormous opportunity that the Chinese healthcare market presents for British healthcare firms – set to grow by $400 billion by 2017. I hope we will see many more partnerships and deals like this for British businesses in this market.”

UK Prime Minister David Cameron with Huai’an Party Secretary Yao Xiao Dong and Sinophi Healthcare Chairman Simon MacKinnon

On December 3rd in Shanghai, UK Secretary of State for Health Mr Jeremy Hunt MP met with Sinophi Healthcare Chairman Simon MacKinnon, Huai’an City Party Secretary Mr Yao Xiao Dong and Huai’an City Mayor Mr Qu Fu Tian.

 Huai’an Party Secretary Mr Yao Xiao Dong with UK Secretary of State for Health Mr Jeremy Hunt MP

Sinophi’s signings were reported by several Chinese domestic and international news services including:

The Financial Times:             “Cameron trumpets healthcare deals with China”

China.org:                                  “UK, China sign multimillion healthcare deals”

Intl. Business Times:             “UK and China agree £120 million Healthcare Deals in Cameron Trade Visit”

The full text of the Prime Minister’s press release from No 10 Downing Street is shown below:

Multimillion boost to UK economy as healthcare trade deals with China sealed

10 Downing Street, 2nd December 2013

The British economy is set to be boosted by more than £120 million thanks to a package of UK/Chinese healthcare deals, Prime Minister David Cameron announced today. The Prime Minister and Health Secretary, Jeremy Hunt witnessed the final agreements being sealed in China, during the Prime Minister’s three day visit to the country.

The deals include:

• Sinophi Healthcare signed contracts for hospital management and hospital investment worth £120 million. These include a joint venture with Huai’an First People’s Hospital, one of the biggest hospitals in Jiangsu Province (population 80 million people) in East China, and an agreement to build a 1,000 bed oncology hospital;
• Heythorp Healthcare signed a Memorandum of Understanding with Jiangsu Far East (Yadong). This is for a joint venture to develop a flagship, mixed use healthcare facility which will include elderly nursing, specialist dementia services and care training outside Jiangsu;
• Healthcare UK signed a Memorandum of Understanding with the CITIC Trust and Circle Partnership to unlock commercial deals for UK companies in areas such as primary care services, integrated care and education and training.
• IXICO signed a Memorandum of Understanding with the Beijing Union Medical and Pharmaceutical General Corporation. They will work together to support dementia diagnosis, advance public understanding of dementia and evaluate new treatments.

On the Sinophi deal, Prime Minister David Cameron said: “This deal highlights the enormous opportunity that the Chinese healthcare market presents for British healthcare firms – set to grow by $400 billion by 2017. I hope we will see many more partnerships and deals like this for British businesses in this market.”

Health Secretary Jeremy Hunt said: “These agreements will see UK firms exporting their expertise to China – building their businesses and investing in Chinese healthcare. Both countries will benefit from these new relationships and better trade links.”

Estimates are that the OECD and BRIC nations will increase spending on healthcare by 50% between 2010 and 2020 to $7.5 trillion. This demonstrates the size of the opportunity for UK firms.

Alongside this effort to improve trade with China, Jeremy Hunt also announced that the UK will embark on a new stream of work with China on Anti-Microbial Resistance (AMR).

Jeremy Hunt said: “Drug resistant infections are a huge threat to global health and an only be dealt with by collaboration across all borders. Working with China and other countries is crucial in fighting AMR, and I am pleased that the UK will be exchanging expertise and developing new areas for action as part of a global partnership.”

Furthermore, Jeremy Hunt also outlined a new partnership with China on care of older people, with a focus on dementia. This is due to be finalised tomorrow.

He said: “Both the UK and China face similar challenges in caring for ageing populations. There is a great deal that we can learn from each other in this field, and we believe UK companies have much to offer in the Chinese elderly care market.”

Source:     https://www.gov.uk/government/news/multimillion-boost-to-uk-economy-as-healthcare-trade-deals-with-china-sealed

Huai’an City

Located in Jiangsu Province in East China, Huai’an City is a fast growing city with an urban population of over 2.5 million and an additional 3 million population in its rural areas.  Sited on the Grand Canal connecting Beijing with Hangzhou (close to Shanghai), it has a long history as a trading and cultural center.

Huai’an First People’s Hospital

HAFPH is one of north Jiangsu’s leading general hospitals.  Located in the city of Huai’an (urban population 2.5m, total population over 5.5m) in the province of Jiangsu (population of over 80 million) next to Shanghai in East China, HAFPH was founded in 1950.  On completion of current expansion, HAFPH will have over 3,000 beds, with well known specialty departments including oncology, cardiovascular, neurology and gastroenterology.

Sinophi Signs LOI with Huaiyin District and Huai’an First People’s Hospital to build a 1,000 bed Regional Oncology Hospital

December 2nd, 2013

In Beijing today, Sinophi Healthcare signed a Letter of Intent with Huai Yin District, Huai’an City and Huai’an First People’s Hospital to build a 1,000 led regional oncology hospital. 

Sinophi Healthcare Chairman Simon MacKinnon signed the LOI with Mr Dong Yangwei (Executive Vice-Director of Huaiyin District Municipal Government) and President Sun Xiaoyang of Huai’an First People’s Hospital.  The signing took place at the Grand Hyatt Hotel in Beijing during the visit of UK Prime Minister Cameron to China to attend the UK-China Summit.

The signing was witnessed by Lord Livingston, UK Minister of State for Trade and Industry, Mr Tang Daolun, Vice Mayor of Huai’an Municipal People’s Government, and Dr Catherine Raines (Minister and Director-General of UKTI China).   

Signing of Letter of Intent in Beijing between Huaiyin District Municipal Government, Huai’an First People’s Hospital and Sinophi Healthcare to build a 1,000 bed regional oncology hospital in Huai’an, Jiangsu Province

Seated (L to R):  Dong Yangwei (Executive Vice-Director of Huaiyin District Municipal Government), Dr Sun Xiaoyang (President, Huai’an First People’s Hospital) and Simon MacKinnon (Chairman, Sinophi Healthcare)

Sinophi Healthcare Chairman Simon MacKinnon stated: “The signing of this agreement is an exciting opportunity to bring together UK and Chinese expertise in cancer treatment to build a world-class cancer hospital in Huai’an City.  The hospital will serve 20 million-plus patients in northern Jiangsu.  We are very grateful for the support the project has received from our partners, from Huai’an City Government, Jiangsu provincial authorities and from the UK Government, UKTI and Healthcare UK.   

President Sun Xiaoyang of HAFPH stated: “HAFPH continues to develop its facilities to serve the people of Huai’an and neighbouring areas.  We look forward to working with Sinophi to build this regional oncology hospital, bringing in expertise from the UK for its design, development and operation including clinical and operational capabilities from the UK’s NHS system.” 

Huai’an City

Located in Jiangsu Province in East China, Huai’an City is a fast growing city with an urban population of over 2.5 million and an additional 3 million population in its rural areas.  Sited on the Grand Canal connecting Beijing with Hangzhou (close to Shanghai), it has a long history as a trading and cultural center.  

Huai’an First People’s Hospital

HAFPH is one of north Jiangsu’s leading general hospitals.  Located in the city of Huai’an (urban population 2.5m, total population over 5.5m) in the province of Jiangsu (population of over 80 million) next to Shanghai in East China, HAFPH was founded in 1950.  On completion of current expansion, HAFPH will have over 3,000 beds, with well known specialty departments including oncology, cardiovascular, neurology and gastroenterology. 

Sinophi Signs LOI with Hongze County Municipal Government to Acquire Hongze TCM Hospital

December 2nd, 2013

In Beijing today, Sinophi Healthcare signed a Letter of Intent with Hongze County Municipal Government to acquire Hongze TCM Hospital in Huai’an City, Jiangsu Province.

Sinophi Healthcare Chairman Simon MacKinnon signed the LOI with Mr Liu Zeyu, Governor of Hongze County, Huai’an Municipal People’s Government and Dr Zhou Baoxiang, President of Hongze TCM Hospital.  The signing took place at the Grand Hyatt Hotel in Beijing during the visit of UK Prime Minister Cameron to China to attend the UK-China Summit.

The signing was witnessed by Lord Livingston, UK Minister of State for Trade and Industry, Mr Tang Daolun, Vice Mayor of Huai’an Municipal People’s Government, and Dr Catherine Raines (Minister and Director-General of UKTI China).

Signing of Letter of Intent in Beijing between Hongze County Municipal Government, Hongze TCM Hospital and Sinophi Healthcare to acquire Hongze TCM Hospital.

Standing (L to R):  Liu Zeyi (Governor of Hongze County Municipal Government), Dr Zhou Baoxiang (President, Hongze TCM Hospital) and Simon MacKinnon (Chairman, Sinophi Healthcare).

Sinophi Healthcare Chairman Simon MacKinnon stated “the signing of this agreement with Hongze District Government marks an important step in the healthcare partnership between Sinophi Healthcare and Huai’an City.  We will be moving forward with Hongze District Government and Hongze TCM Hospital to purchase the hospital next year.  Sinophi will be working with UK company and NHS partners, bringing together UK and international expertise with our hospital management partner (Huai’an First People’s Hospital)’s well established reputation and skills in north Jiangsu province in East China.  We are very grateful for the strong support we have received from both the Huai’an Municipal People’s Government and from UK Government, especially UKTI, FCO and Healthcare UK.”  

Hongze County Governor, Mr Liu Zeyu commented: “We are delighted to welcome Sinophi to invest in Hongze TCM Hospital as part of delivering further improvements to the local healthcare system and improved healthcare for the people of Hongze.”

Lord Ian Livingston (UK Secretary of State for Trade and Industry) and Tang Daolun (Vice Mayor of Huai’an Municipal People’s Government), (3rd and 4th frm left) celebrate the signing of the LOI to acquire Hongze TCM Hospital with members of the Hongze District Municipal Government, Huai’an City officials and Sinophi Healthcare at the UK-China Summit in Beijing

Huai’an City

Located in Jiangsu Province in East China, Huai’an City is a fast growing city with an urban population of over 2.5 million and an additional 3 million population in its rural areas.  Sited on the Grand Canal connecting Beijing with Hangzhou (close to Shanghai), it has a long history as a trading and cultural center.   

Huai’an First People’s Hospital

HAFPH is one of north Jiangsu’s leading general hospitals.  Located in the city of Huai’an (urban population 2.5m, total population over 5.5m) in the province of Jiangsu (population of over 80 million) next to Shanghai in East China, HAFPH was founded in 1950.  On completion of current expansion, HAFPH will have over 3,000 beds, with well known specialty departments including oncology, cardiovascular, neurology and gastroenterology.

Sinophi Signs Joint Venture with Huai’an First People’s Hospital to do Hosptial Management in China

December 2nd, 2013

Sinophi today signed a joint venture in Beijing with Huai’an First People’s Hospital (HAFPH) to do hospital management in China.   

Sinophi Healthcare CEO Dr Hanif Kanji signed the joint venture contract with Dr Sun Xiaoyang, President of Huai’an First People’s Hospital at the Grand Hyatt Hotel in Beijing during the visit of UK Prime Minister Cameron MP to China.

The signing was witnessed by Lord Livingston, UK Minister of State for Trade and Industry, and by Vice Mayor Tang Daolun of Huai’an Municipal People’s Government.   

Signing of Joint Venture Agreement in Beijing between Huai’an First People’s Hospital and Sinophi Healthcare

Seated (L to R):  Dr Sun Xiaoyang (President, Huai’an First People’s Hospital), Dr Hanif Kanji (CEO, Sinophi Healthcare), 

Standing:  Witnessing the signing included Dr Catherine Raines (Minister and Director-General of UKTI China), Lord Ian Livingston (UK Minister of State for Trade and Industry), Tang Daolun (Vice Mayor of Huai’an Municipal People’s Government), Ji Wenqiao (Director, Huai’an Health Bureau) and Simon MacKinnon (Chairman, Sinophi Healthcare)

UK Prime Minister David Cameron MP commented “Sinophi’s signing highlights the enormous opportunity that the Chinese healthcare market presents for British healthcare firms – set to grow by $400bn by 2017. I hope we will see many more partnerships and deals like this for British businesses in this market.”

Sinophi Healthcare CEO Dr Hanif Kanji commented “the signing of this JV marks the next stage of our co-operation with HAFPH, bringing together UK and international expertise with HAFPH’s well established reputation and skills in north Jiangsu province in East China.  We are very grateful for the strong support we have received from both the Huai’an Municipal People’s Government and from the UK Government, especially UKTI, FCO and Healthcare UK.” 

President Sun Xiaoyang of HAFPH stated “We are looking forward to working with Sinophi’s international and Chinese teams to deliver hospital management expertise to Huai’an and north Jiangsu hospitals.  We will work with local hospitals to support them in upgrading their delivery of healthcare services to many millions of people across the region.”

UK Secretary of State for Health, The Rt. Hon. Jeremy Hunt MP (centre), celebrates the signing of the Joint Venture Agreement between Huai’an First People’s Hospital and Sinophi Healthcare at the UK-China Summit in Beijing

Huai’an City

Located in Jiangsu Province in East China, Huai’an City is a fast growing city with an urban population of over 2.5 million and an additional 3 million population in its rural areas.  Sited on the Grand Canal connecting Beijing with Hangzhou (close to Shanghai), it has a long history as a trading and cultural center.  

Huai’an First People’s Hospital

HAFPH is one of north Jiangsu’s leading general hospitals.  Located in the city of Huai’an (urban population 2.5m, total population over 5.5m) in the province of Jiangsu (population of over 80 million) next to Shanghai in East China, HAFPH was founded in 1950.  On completion of current expansion, HAFPH will have over 3,000 beds, with well known specialty departments including oncology, cardiovascular, neurology and gastroenterology.